A Phase 1 Open-Label Dose-Escalation Study of the Safety and Pharmacokinetics of SNX-5422 Mesylate in Subjects With Refractory Solid Tumor Malignancies Or Non-Hodgkin's Lymphoma.
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2014
At a glance
- Drugs SNX 5422 (Primary)
- Indications Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Esanex
- 02 Oct 2014 Status changed from completed to discontinued as per European Journal of Cancer.
- 24 Sep 2014 Pooled analysis results published in the European Journal of Cancer.
- 16 May 2012 Company (Esanex) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History